

Case Study: Asthma

Phase 3 | Respiratory | Pivotal

Challenge

Brick & mortar sites experience significant fatigue in asthma studies, with many sites participating in multiple, similar protocols, leading to:

Burnout Among Site Staff And Investigators: reduced engagement and prioritization of the study.

Difficulty Enrolling Patients: the local population were already heavily utilized or unwilling to participate due to study burden.

Poor Patient Compliance: due to long travel times, inconvenient visit schedules, and lack of engagement related to the repetitive nature of the studies at these sites

Solution

Science 37's Direct-to-Patient Site provided a scalable, patient-centric alternative by removing geographic limitations and accessing untapped patient populations, including:

Expedited Study Start-Up: Leveraging our in-house team of research-grade mobile nurses and remote Science 37 investigator oversight.

Rapid, Robust Enrollment: Identifying and enrolling fresh patients across the entire U.S.

Improved Compliance And Retention: Conducting study visits in the comfort of the participant's home, minimizing disruptions to daily life, and making participation more convenient.

Science 37 Results

Enrolled

28%

of Total Study Participants

Science 37 total pts – 712
55 brick & mortar total pts – 1,815

22x

Faster Enrollment Compared
to Traditional Sites

Science 37 avg. pts/month – 44
Single brick & mortar site avg. pts/month – 2

**Top
Enrolling
Site**

Among 56 Sites



Scan to Learn More about Our Direct-to-Patient Site.

© 2026 Science 37. All rights reserved. This material is confidential and proprietary to Science 37 and shall not be distributed, edited or modified in any way without Science 37's advance written consent.

www.science37.com

The First & Only FDA-Inspected
Direct-to-Patient Site

Case Study: Asthma

Phase 3 | Respiratory | Pivotal

Number of Patients Science 37 Enrolled Per State

